Myriad Genetics is partnering with OptraHealth to develop a chatbot named Gene that will offer patients information on hereditary cancer.
Gene includes OptraHealth's GeneFax artificial intelligence (AI) platform that helps it answer more than 500,000 questions about hereditary cancer. It works with Myriad's online hereditary cancer quiz, the company said. For potential patients who meet criteria for further evaluation, Gene will send an educational link that directs users to interactive content for further education and the option to talk with a patient educator.
Myriad plans to launch Gene for its Foresight and Prequel prenatal tests and for oncologic diagnostic testing later this year.